

The completion of the Human Genome Project and the advent of the post-genome era have seen “Precision Medicine”, a concept based on personalized medicine, rise as a trend in the field of cancer treatment research. Researchers’ current efforts are focused on the use of molecular typing to identify sub-classifications of tumors, with the aim of discovering more effective drugs and treatment methods at the molecular level. The ultimate goal is to achieve precision therapy for cancer patients.

With the highest morbidity and mortality rates of any malignancy, lung cancer imposes a major disease burden worldwide. In recent years, however, rapid progress has been made in the field of precision therapy for lung cancer. Studies on novel targeted drugs, such as tyrosine kinase inhibitors, anti-angiogenesis targeting drugs, and immune checkpoint inhibitors, are emerging constantly. Moreover, the efficacy data on precision therapy for lung cancer are continuously being updated. To aid clinicians’ understanding and rapid learning of the latest developments in the field of lung cancer precision therapy, we have compiled a collection of the most innovative original articles, and invited international experts in the field of lung cancer transformation from more than 20 countries to write a letter sharing their insights.

This book comprises four parts: epidemiology and surveillance, cancer biology, molecular targets, and treatment. It explores the latest progress in precision therapy for lung cancer, from the study of molecular mechanisms to its clinical application. We believe that doctors and researchers who read this book will gain new and invaluable insights and guidance.



**Desheng Xiao, MD, PhD**  
Department of Pathology, Xiangya Hospital,  
Central South University, China



**Chunlin Ou, MD, PhD**  
Department of Pathology, Xiangya Hospital,  
Central South University, China